Peresolimab
Highest phase reached
Phase 2
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Antibody
- Drug name
- Peresolimab
- immunoglobulin g1 anti human programmed cell death protein 1 human monoclonal ly3462817 gamma 1 chain disulfide with human monoclonal ly3462817 kappa chain dimer
- IMMUNOGLOBULIN G1, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL LY3462817 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL LY3462817 .KAPPA.-CHAIN, DIMER
- ly 3462817
- LY-3462817
- ly3462817
- LY3462817
- LY3462817 - IV
- LY3462817 (IV)
- LY3462817 IV
- peresolimab
- Peresolimab
- peresolimab [INN]
- PERESOLIMAB [USAN]
- Peresolimab [WHO-DD]
- peresolimab inn
- peresolimab usan
- peresolimab who dd
- CAS registry numbers
- 2411580-63-5
- ChEMBL ID
- CHEMBL5095360
- FDA ingredient codes (UNII)
- DI4N99Q6KK
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -mab
- Condition
- Psoriasis
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000676
- Subject identifier
- D011565
- Condition
- Arthritis, Rheumatoid
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000685
- Subject identifier
- D001172
- Condition identifier
- EFO_0000676
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000685
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005083
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0008383
- Highest recorded phase
- 2
- NCT04152382
- NCT04634253
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Glycosylation sites (N)
- Sequence
- 299 $ 299''''
- Component
- Heavy chain
- Type
- Protein
- Sequence
- QVQLVQSGAEVKKPGASVKVSCKVSGYSLSKYDMSWVRQAPGKGLEWMGIIYTSGYTDYAQKFQGRVIMTEDTSTDTAYMELSSLRSEDTAVYYCATGNPYYTNGENSWGQGTLVTVSSASTKGPSVEPLAPSSKSTSGGTAALGCLVKDYFPEPVIVSWNSGALTSGVHTEPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVESCSVMHEALHNHYTQKSLSLSPGK
- Component
- Light chain
- Type
- Protein
- Sequence
- DIQMTQSPSSLSASVGDRVTITCQASQSPNNLLAWYQQKPGKAPKLLIYGASDLPSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNNYYVGPVSYAFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
- Component
- Disulfide bridges
- Sequence
- 22-95 $ 22''-95'' $ 23'-88' $ 23'''-88''' $ 137'-197' $ 137'''-197''' $ 146-202 $ 146''-202'' $ 222-217' $ 222''-217''' $ 228-228'' $ 231-231'' $ 263-323 $ 263'-323' $ 369-427 $ 369''-427''
- Component
- Glycosylation sites (N)
- Sequence
- 299 $ 299''
Related records
Trials (6)
- A Relative Bioavailability Study of Peresolimab (LY3462817) Formulations in Healthy Participants
- A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis
- A Safety Study of LY3462817 in Healthy Japanese and Non-Japanese Participants
- A Safety Study of LY3462817 in Healthy Participants
- A Study of LY3462817 in Participants With Rheumatoid Arthritis
- A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis
In development for (2)
- Psoriasis Phase 1
- Rheumatoid arthritis Phase 2